Intas to provide 2 million hydroxychloroquine tablets for WHO study on COVID-19

Intas informed that it is collaborating on the WHO-endorsed study using hydroxychloroquine, a drug that may have an effect in preventing and/or reducing symptoms of COVID-19. The global COPCOV (chloroquine / hydroxychloroquine prevention of COVID-19 in the healthcare setting; a randomised, placebo-controlled prophylaxis).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2QXJMIW
via IFTTT